Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Overweight 2Obesity 2Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Letrozole 5Radiotherapy 4Carboplatin 4atamestane 3Trastuzumab 3Toremifene 3Docetaxel 3Cyclophosphamide 3Chemotherapy, Adjuvant 3Tamoxifen 2Paclitaxel 2Gene Expression Profiling 2Fulvestrant 2Estrogen Receptor Modulators 2Capecitabine 2Aromatase Inhibitors 2Amplified Fragment Length Polymorphism Analysis 2palbociclib 1Zolpidem 1Vorinostat 1Vinorelbine 1Venlafaxine Hydrochloride 1Thiotepa 1Taxes 1Sugars 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy, Conformal 1Radiosurgery 1Radiomics 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Lobular × Naltrexone × Breast × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡